COVID-19 疫苗接种后急性期后非特异性症状:一项丹麦人群研究
该研究基于 BiCoVac 队列(丹麦 16-65 岁公民随机样本 913116 人)的重复测量数据,于 2021 年 5 月至 2022 年 6 月通过全国登记和问卷收集数据,按疫苗犹豫程度分层分析接种与未接种者急性期后非特异性症状的比值比。结果显示,不担忧疫苗者接种后多数症状比值比降低(如肌肉疼痛 OR=0.56,95%CI 0.47-0.68),担忧疫苗者接种后多数症状比值比有升高趋势(如肌肉疼痛 OR=1.23,95%CI 0.91-1.67),作者认为后者可能与报告偏倚或反安慰剂效应有关。
要点
- 不担忧疫苗者接种后超过 4 周多数非特异性症状的比值比低于未接种者,如肌肉疼痛 OR=0.56(95%CI 0.47-0.68)。
- 担忧疫苗者接种后超过 4 周多数症状比值比有升高趋势,如肌肉疼痛 OR=1.23(95%CI 0.91-1.67)。
- 作者结论认为多数 16-65 岁个体接种后无急性期后症状证据,担忧疫苗者症状报告增多可能与报告偏倚或反安慰剂效应有关。
核心结论
- 对多数 16-65 岁个体,未发现 COVID-19 疫苗接种后急性期后症状的证据;但担忧疫苗的接种者更可能报告多数症状,可能与报告偏倚或反安慰剂效应有关。
研究设计与样本
- 纵向研究,使用 BiCoVac 队列(丹麦 16-65 岁公民随机样本 913116 人)的重复测量数据,通过全国登记和问卷于 2021 年 5 月至 2022 年 6 月收集数据。
- 非特异性症状采用 25 项躯体痛苦综合征检查表识别,使用 logistic 和线性回归模型比较接种与未接种个体,模型采用稳健标准误和逆概率选择权重。
- 共收集 132776 次观察(来自 61316 名不担忧疫苗者)、52325 次观察(来自 25272 名怀疑疫苗者)和 10242 次观察(来自 5064 名担忧疫苗者)。
主要发现
- 不担忧疫苗者中,接种者接种后超过 4 周多数症状的比值比低于未接种者,如肌肉疼痛 OR=0.56(95%CI 0.47-0.68)。
- 怀疑疫苗者中呈现相似趋势,但估计值减弱。
- 担忧疫苗者中,接种者接种后超过 4 周多数症状的比值比有升高趋势,如肌肉疼痛 OR=1.23(95%CI 0.91-1.67)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-acute non-specific symptoms such as headaches, muscular pain, and fatigue are frequently reported following COVID-19 vaccination, raising concerns about adverse events. As vaccine-hesitant individuals may be more likely to experience symptoms of vaccines, this study investigates whether COVID-19 vaccination increases the odds of post-acute non-specific symptoms, stratified by COVID-19 vaccine hesitancy. METHODS: This longitudinal study uses repeated measurements from the BiCoVac cohort-a random sample of 913 116 Danish citizens aged 16-65 years. Data were collected through national registers and questionnaires (May 2021-June 2022). Non-specific symptoms were identified by using the 25-item Bodily Distress Syndrome checklist and analysed by using logistic and linear regression models comparing vaccinated and unvaccinated individuals. Models were fitted with robust standard errors and inverse probability of selection weights. RESULTS: A total of 132 776 observations were collected from 61 316 COVID-19 vaccine-unconcerned individuals, 52 325 observations from 25 272 COVID-19 vaccine-sceptical individuals, and 10 242 observations from 5064 COVID-19 vaccine-concerned individuals. Among the vaccine-unconcerned individuals, those vaccinated had lower odds of most symptoms compared with unvaccinated individuals >4 weeks post-vaccination [e.g. muscular pain: odds ratio (OR) = 0.56, 95% confidence interval (CI): 0.47-0.68]. A similar tendency was found for vaccine-sceptical individuals, although with attenuated estimates. Conversely, among vaccine-concerned individuals, we observed a tendency for higher odds of most symptoms >4 weeks post-vaccination compared with unvaccinated individuals (e.g. muscular pain: OR = 1.23, 95% CI: 0.91-1.67). CONCLUSION: For most individuals aged 16-65 years, we found no evidence of post-acute symptoms after COVID-19 vaccination. Vaccinated vaccine-concerned individuals were, however, more likely to report most symptoms, potentially due to reporting bias or nocebo effects.
引用
- Jensen CB, Hansen KT, Bech BH, et al. Post-acute non-specific symptoms following COVID-19 vaccination: a Danish population-based study. Int J Epidemiol. 2025. PMID: 41070980. doi:10.1093/ije/dyaf173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。